癌症患者使用伐尼克兰治疗尼古丁依赖

2016/07/27

   摘要
   背景:癌症诊断后继续吸烟会对癌症患者的预后产生不利影响。然而,很少有研究仔细考察美国食品和药物管理局批准的治疗尼古丁依赖的一线药物对癌症患者的影响。这项研究评估伐尼克兰停用对癌症患者戒烟的可行性、安全性和影响。
   方法:数据来源于132例寻求治疗的吸烟者,他们接受了为期12周的开放式的伐尼克兰治疗,五次短暂行为咨询会议用于评估伐尼克兰停用的可行性、安全性和影响。同时也探究了戒烟对认知功能和情感的影响。
   结果:筛选的459例患者中,有306人符合研究要求(66.7%),132个进入治疗(43.1%)。12周的受试者留存率为84.1%。12周时的生化验证戒烟率为40.2%。产生了预期的副作用(如睡眠问题、恶心),但没有增加抑郁情绪、自杀的想法、或心血管事件的报告。随着时间的推移,戒烟与改善认知功能和减少负面情绪有关(P<0.05)。
   结论:尽管许多筛选的吸烟癌症患者没有参加本项治疗,但研究结果显示伐尼克兰的副作用和它对戒烟的短期效果与普通人群相似。此外,与普通人群一样,戒烟的同时服用伐尼克兰可能导致认知功能的改善并减少负面情绪。目前的数据支持使用伐尼克兰来帮助癌症患者戒烟。

 
(苏欣 审校)
Psychooncology. 2016 May 24. doi: 10.1002/pon.4166. [Epub ahead of print]


 
 
 
 
The use of varenicline to treat nicotine dependence among patients with cancer.
 
 
Price S1, Hitsman B2,3, Veluz-Wilkins A2, Blazekovic S1, Brubaker TR1, Leone F4, Hole A1, Wileyto EP5, Langer C6, Kalhan R2,7, Patel J3,7, Schnoll R1.
Author information
 
 
Abstract
BACKGROUND:Continuing to smoke after a cancer diagnosis can adversely influence the prognosis for patients with cancer. However, remarkably few studies have carefully examined the use of first-line FDA-approved medications for nicotine dependence in patients with cancer. This study evaluated the feasibility, safety, and effect on cessation of varenicline for smoking cessation in patients with cancer.
METHODS:Data from 132 treatment-seeking smokers who received 12 weeks of open-label varenicline and five brief behavioral counseling sessions were used to evaluate the feasibility, safety, and impact on cessation of varenicline. The effects of abstinence on cognitive function and affect were also explored.
RESULTS:Of 459 patients screened, 306 were eligible for the study (66.7%) and 132 entered treatment (43.1%). Retention was 84.1% over 12 weeks. The rate of biochemically verified abstinence at week 12 was 40.2%. Expected side effects were reported (e.g. sleep problems, nausea), but there were no reports of elevated depressed mood, suicidal thoughts, or cardiovascular events. Abstinence was associated with improved cognitive function and reduced negative affect over time (p < 0.05).
CONCLUSIONS:Although many patients with cancer who smoke did not enroll in treatment, the side effect profile of varenicline and its effect on short-term cessation converge with what is seen in the general population. Further, as with the general population, abstinence while taking varenicline may lead to improved cognitive function and reduced negative affect. The present data support the use of varenicline to help patients with cancer to quit smoking. Copyright © 2016 John Wiley & Sons, Ltd.
KEYWORDS:affect; cancer; cognition; oncology; smoking cessation; varenicline
 
 
Psychooncology. 2016 May 24. doi: 10.1002/pon.4166. [Epub ahead of print]
 


上一篇: 伐尼克兰和尼古丁替代治疗在老年和青年吸烟者戒烟过程中的疗效比较: 一项台湾前瞻性队列研究
下一篇: 肺癌患者:电子香烟有利还是有弊?

用户登录